Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vacc

T-Reuters2021-05-20

Merck & Co Inc :Merck Announces Positive Topline Results From Pneu-Direction (V114-027) And Pneu-Plan (V114-024) Phase 3 Pediatric Studies For V114, Merck’S Investigational 15-Valent Pneumococcal Conjugate Vaccine.Merck & Co Inc - V114 Met Primary Immunogenicity And Safety Endpoints In Both Trials.Merck & Co Inc - V114 Was Generally Well-Tolerated, With A Safety Profile Comparable To Pcv13.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
2